BJH - 2022, issue SPECIAL, april 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
The Belgian Society of Human Genetics (BeSHG) was launched in March 2000 and aims at promoting human genetics in its wider sense, i.e. by supporting genetic research, improving exchanges between Belgium and foreign countries, organising scientific meetings, and enhancing collaboration between Belgian labs. During the 37th general annual meeting of the Belgian Haematology Society, a joint BeSHG-BHS session was organised. In this session, Karlijn Brekelmans (University Hospital Leuven, Leuven, Belgium) first discussed how genetic predisposition in haemato-oncological disorders can be detected, with a focus on technique, type of tissue that can be used and turn-around-time. Her talk was followed by a presentation from Esmé Waanders (Princess Maxima Centre, Utrecht, The Netherlands) discussing geentic predisposition in lymphoid malignancies.
Read moreBJH - 2022, issue SPECIAL, april 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In recent years, we have witnessed many advances in laboratory technology to detect germline or somatic mutations that predispose individuals to the development of haematopoietic malignancies. The laboratory technology session during the BHS GAM kicked off with a presentation from Dr. Ann Debecker explaining the differences between CHIP, CHOP and ARCH. In a second lecture of the laboratory technology session, Dr. Ine Moors provided a contemporary overview on genetic predisposition for myeloid malignancies.
Read moreBJH - 2022, issue SPECIAL, april 2022
A. Enguita PhD, T. Feys MBA, MSc
Myelofibrosis (MF) is a chronic malignancy characterised by marrow fibrosis and myeloproliferation caused by a constitutive activation of the Janus-activated kinase (JAK) transcription signalling pathway. This constitutive activation is usually the result of mutations in the driver genes JAK2, myeloproliferative leukaemia virus (MPL) or calreticulin (CALR).1 The most important clinical manifestation of MF consists of splenomegaly, in addition to hepatomegaly, cytopenia (mainly anaemia), and constitutional symptoms.2 MF significantly decreases the life expectancy of patients with a median survival of less than six years.3 During the 37th general annual meeting of the Belgian Haematology Society, professor Jean-Jacques Kiladjian (Saint Louis Hospital, Paris, France) discussed the contemporary management of this disease.
Read moreBJH - 2021, issue SPECIAL, january 2021
dr. J. Van Dorpe
Cell-free plasma DNA (cfDNA) and circulating tumour DNA (ctDNA) represent potential alternative sources of diagnostic information. During his lecture at the 2021 BHS general annual meeting Dr. Jo Van Dorpe discussed the potential of these liquid biopsies in the diagnostic work-up of different lymohoma subtypes.
Read moreBJH - 2021, issue SPECIAL, january 2021
prof. F. Baron
During the the 36th general annual meeting of the Belgian Haematology Society prof. Frédéric Baron addressed an interesting question; which conditioning regimen should be chosen for which acute myeloid leukaemia (AML) patient? As you will find out in this report, the answer to this question is not so straight forward.
Read moreBJH - 2021, issue SPECIAL, january 2021
prof. M.V. Mateos
Multiple myeloma (MM) is a clonal plasma cell malignancy affecting a predominantly elderly population. The continued development of newer therapies with novel mechanisms of action has reshaped the treatment paradigm of this disorder in the last two decades, leading to a significantly improved prognosis. Immune-based therapies, including monoclonal antibodies, and more recently also adoptive cellular therapies have emerged as therapeutic strategies in MM. During her lecture at the 2021 BHS GAM, Prof. Maria-Victoria Mateos gave an overview of the current state of affairs related to immune related therapies in MM.
Read moreBJH - 2021, issue SPECIAL, january 2021
T. Mercier MD, PhD
The global COVID-19 pandemic had a major impact on all the aspects of the healthcare system and hematology departments were no exception to this. In order to get more insights into the risk for severe COVID-19 infections among patients with hematological conditions, the Belgian Hematology Society set up the BHS COVID-19 registry. During the 2021 BHS general annual meeting preliminary results of this registry were presented.
Read more
Top
